The long-term impact of stress exposure at central and peripheral level: novel biomarkers to identify intervention strategies in major depression

Nadia Cattane,Naguib Mechawar,Henning Großkopf,Andreas Menke

DOI: https://doi.org/10.1016/j.psyneuen.2023.106704

IF: 4.693

2024-02-01

Psychoneuroendocrinology

Abstract:Exposure to chronic stress, including early life adverse experiences, has long-lasting effects on brain structure and functions and it is associated with a higher risk for psychiatric disorders, such as major depression, later in life. Human and rodent studies have indeed demonstrated that chronic stress during sensitive developmental periods impacts multiple biological processes, causing alterations in the neuroimmune system, including microglia, and in stress response mechanisms. Indeed, long-term effects of chronic stress on immune functions are usually associated with a low grade inflammation in combination with persistent disruptions in the hypothalamic-pituitary- adrenal (HPA) axis. In this context, childhood trauma represents one of the main early life stress event that can cause alterations in such previously mentioned biological processes and, therefore, it can contribute to the onset of major depression later on. It has also been associated with a lack of response to antidepressant drugs. Although the contribution of chronic stress in the development of major depression has been quite extensively described, there is a great need to further understand the affected mechanisms and to dissect the consequences of their alterations at central and peripheral levels. This might lead to the identification of novel biomarkers and to the development of new intervention strategies useful to stop or delay the onset of clinical symptoms and to predict/improve the treatment response. Moreover, this might be helpful in the differential diagnosis of major depression, identifying specific biomarkers able to differentiate depressed subjects from other psychiatric patients. By using a multidisciplinary approach, our symposium will cover these important issues. Indeed, from a preclinical and clinical perspective, we will provide evidence about the involvement of novel biomarkers, i.e. SGK1 and FKBP5, in major depression and we will give a clearer picture about the role of microglia in depressed patients with a history of childhood trauma. Moreover, by using a cross-tissues approach, spanning from post-mortem brains, cerebrospinal fluid (CSF) and peripheral blood, we will try to identify a biomarker profile specifically associated with the development of major depression and with a lack of response to antidepressant drugs. Finally, our symposium will highlight how a multidisciplinary approach focused on different expertise and experimental techniques, including methylation, gene expression, immunofluorescence and proteomics data, can increase the knowledge about the long-term impact of chronic stress in major depression.

neurosciences,endocrinology & metabolism,psychiatry